Fennec swings to FY26 Q2 net income of $1.97 million; net sales rise 78% to $17.1 million year over year
FENC•Expenses and commercial update
Selling and marketing expense climbed to $10.7 million as the company expanded its sales organization and PEDMARK awareness initiatives.
Management cited record PEDMARK demand carrying into Q3 as field sales expansion continues; ASCO 2026 data supported integration without compromising cisplatin activity.
Q2 net sales and profit turn positive
Fennec reported Q2 2026 net sales of $17.1 million, up 78% year over year.
GAAP net income turned to $2 million, or $0.06 per share.
Non-GAAP adjusted EBITDA swung to $2.8 million.
